New insider activity at RenovoRx ( (RNXT) ) has taken place on April 15, 2025.
CMO Ramtin Agah has made a significant investment in RenovoRx by purchasing 20,000 shares of the company’s stock, valued at $16,000. This move highlights Agah’s confidence in the company’s future prospects.
Recent Updates on RNXT stock
RenovoRx has announced a delay in filing its Form 10-K for the financial period ending December 31, 2024, due to the need to complete technical accounting requirements with current and former auditing firms. The company expects to file within the SEC’s fifteen-day grace period and anticipates initial revenue from its RenovoCath commercial efforts, with a slight decrease in net loss due to reduced expenses. H.C. Wainwright initiated coverage with a Buy rating, citing the company’s potential in the $740M market for its novel catheter system targeting pancreatic cancer. The firm projects significant revenue growth from $4M in 2025 to $253M in 2034, suggesting the shares are undervalued and appealing for long-term investors.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Underperform.
RenovoRx’s overall stock score reflects significant financial challenges, with persistent operational losses and negative cash flows. Technical analysis suggests ongoing bearish trends, while valuation is hampered by a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events further underscores the company’s uncertain outlook.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
YTD Price Performance: -43.24%
Average Trading Volume: 144,023
Technical Sentiment Signal: Buy
Current Market Cap: $28.21M